Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.
Price history
Loading NCNA daily closes…
Loading price history…
Pipeline assets
NUC-7738
Phase 2 · ActiveModality: small molecule (ProTide)
Target nucleotide metabolism (ProTide prodrug)
Partnerships License and collaboration agreement with Cardiff ProTides Ltd. (core IP for ProTide platform).
Indications
Advanced solid tumors (monotherapy)(Phase 2)
Melanoma (in combination with pembrolizumab)(Phase 2)
Status note ProTide candidate in the Phase 2 part of the NuTide:701 Phase 1/2 trial in patients with advanced solid tumors, evaluated as monotherapy and in combination with pembrolizumab in melanoma. The company depends heavily on the success of NUC-7738 and NUC-3373.
NUC-3373
Phase 1 · ActiveModality: small molecule (ProTide)
Target nucleotide metabolism (ProTide prodrug)
Indications
Advanced solid tumors (in combination with pembrolizumab)(Phase 1)
Lung cancer (in combination with docetaxel)(Phase 1)
Status note ProTide candidate recently evaluated in the Phase 1b/2 modular NuTide:303 trial in combination with pembrolizumab for advanced solid tumors and with docetaxel for lung cancer; company evaluating optimal combinations and indications for further trials. The company depends heavily on the success of NUC-3373 and NUC-7738.
Per-asset detail extracted from the 20-F filed 2026-03-19. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.